What antiepileptic medications are recommended and how should they be dosed for a pregnant woman with epilepsy to minimize fetal risk?

Use of Antiepileptics During Pregnancy

For pregnant women with epilepsy, lamotrigine or levetiracetam should be the preferred antiseizure medications (ASMs), while valproic acid must be avoided due to its high teratogenic risk, and all women must receive at least 4 mg of folic acid daily starting at least one month before conception. 1, 2

Critical Preconception and Early Pregnancy Management

Folic Acid Supplementation

• Prescribe 4 mg of folic acid daily (not the standard 0.4 mg) starting at least one month before conception and continuing through the first trimester 1
• This higher dose is specifically for women with epilepsy on ASMs due to increased neural tube defect risk
• Standard 0.4-0.8 mg doses are insufficient for this population 3

Medication Selection Priority

First-Line ASMs (Safest Options):

• Lamotrigine: Preferred for most seizure types; associated with minimal risk of major congenital malformations (MCMs) 2
• Levetiracetam: Equally safe alternative with favorable fetal outcomes 2
• Oxcarbazepine: Acceptable third option when appropriate for seizure type 2

Medications to Avoid:

• Valproic acid (valproate): MUST be avoided if clinically feasible 2
  • Highest risk of MCMs (neural tube defects in particular)
  • Causes autism spectrum disorder and lower IQ in offspring
  • Associated with small-for-gestational-age infants 2
• Topiramate: Should be avoided due to increased risk of small-for-gestational-age infants 2
• Phenytoin, carbamazepine, phenobarbital: Higher teratogenic risk than lamotrigine/levetiracetam 1

Dosing Strategy During Pregnancy

Lamotrigine Management

Based on real-world data from women with favorable seizure outcomes 4:

• Expect to increase dose by approximately 100% (median 191% of conception dose by delivery)
• Begin monitoring early: first dose increase typically occurs around 32 days post-enrollment (approximately 18-20 weeks gestation)
• Increase by 100 mg/day increments (median adjustment)
• Monitor serum levels regularly as lamotrigine concentrations can decrease by >50% during pregnancy 5

Levetiracetam Management

• Expect to increase dose by approximately 75% (median 177% of conception dose by delivery) 4
• Increase by 500 mg/day increments (median adjustment)
• Concentrations may decrease by >50% during pregnancy 5

Monitoring Schedule

• Therapeutic drug monitoring is essential, particularly for lamotrigine and oxcarbazepine 6, 5
• Check levels monthly or more frequently if seizures worsen
• Adjust doses to maintain pre-pregnancy therapeutic levels
• Most dose increases occur in second and third trimesters when hemodynamic load is highest

Postpartum Dose Tapering

Timing and Approach

• Begin dose reduction within 3 days postpartum (median timing) 4
• For lamotrigine: Taper by 100 mg/day increments to approximately 116% of conception dose by 6 weeks postpartum 4
• For levetiracetam: Taper by 500 mg/day increments to approximately 136% of conception dose by 6 weeks postpartum 4
• 70.5% of women on lamotrigine and 34.4% on levetiracetam required postpartum dose tapers 4

Critical Clinical Principles

Seizure Control vs. Medication Risk

• Preventing generalized tonic-clonic seizures is paramount 2
• Uncontrolled convulsive seizures pose greater risk to mother and fetus than most ASMs (except valproate)
• Do NOT attempt to switch or remove an effective ASM once pregnancy is confirmed if it controls tonic-clonic seizures 2
• All medication optimization should occur preconceptionally

Monotherapy vs. Polytherapy

• Use monotherapy at the lowest effective dose whenever possible 1, 6
• Polytherapy increases risk of congenital malformations
• If polytherapy is necessary, avoid combinations including valproate

Common Pitfalls to Avoid

1. Waiting until pregnancy to optimize medications: All switches should be completed before conception 1
2. Using standard folic acid doses: Women with epilepsy need 4 mg, not 0.4 mg 1
3. Failing to increase doses during pregnancy: Pharmacokinetic changes require proactive dose increases, especially for lamotrigine 4, 5
4. Continuing valproate when alternatives exist: The teratogenic risks are too high 2
5. Forgetting postpartum dose reduction: Failure to taper can lead to toxicity as pregnancy-related pharmacokinetic changes reverse 4

Factors Affecting Seizure Control

If seizures worsen during pregnancy, evaluate:

• Medication non-compliance (most common)
• Insufficient sleep
• Emesis affecting drug absorption
• Declining drug levels due to pregnancy-related pharmacokinetic changes 5

Special Considerations

• Approximately one-third of women experience increased seizure frequency during pregnancy 1
• Most women (majority) maintain stable seizure control 6
• Seizure disorders themselves increase risk of congenital anomalies even without medication 1
• The risk-benefit calculation strongly favors maintaining seizure control with appropriate ASMs over attempting to avoid all medications